The complexes, [VO(O(2))(pa)(2)]ClO(4).3H(2)O (1), [VO(O(2))(pa)(2)][VO(O(2))(2)(pa)].3H(2)O (2), [VO(O(2))(pa)(2)][VO(O(2))(ada)].2H(2)O (3) and [VO(O(2))(pa)(pca)].H(2)O (4)[pa = picolinamide, ada = carbamoylmethyliminodiacetate(2-) and pca = 2-pyrazinecarboxylate(1-)], were synthesized. 2 and 3 are new types of peroxovanadium complexes: monoperoxovanadium diperoxovanadate (2) and monoperoxovanadium monoperoxovanadate (3). The complexes were characterized by chemical analysis and IR spectroscopy, and 1, 3 and 4 also by X-ray analysis. The structure of 1 is disordered, with alternating positions of the oxo and peroxo ligands. The peroxo oxygen atoms, O(p), in 1 are involved in weak hydrogen bonds with water molecules and close intramolecular C-HO...(p) bonds [d(HO(p)) approximately 2.0 A]. The supramolecular structure of 1 is formed by a network of hydrogen bonds and strong attractive intermolecular pi-pi interactions between the pyridine rings. The supramolecular architecture in 4 is constructed by (N,O)-H...O hydrogen bonds between the neutral complex molecules and water of crystallization. The peroxo oxygen atoms in 4 form intramolecular C-H...O(p) bonds [d(H...O(p))= 2.303 A]. The pa and pca ligands are ON coordinated via the oxygen atoms of the C(NH(2))=O and COO(-) groups, respectively, and nitrogen atoms of the heterocyclic rings, and ada as a tetradentate O(3)N ligand. The thermal analysis of 4 showed that the loss of water of crystallization and the active oxygen release (T(min)/ degrees C 82, T(max)/degrees C 165) are, under given conditions, individual processes separated by the temperature interval 90-132 degrees C. The solution structures and stability were studied by UV-VIS and (51)V NMR spectroscopies.

The kinetics of the alkaline hydrolysis and the configuration, conformation and electronic structure were studied using IR, NMR spectroscopy, X-ray analysis and AM1 theoretical calculations for a series of (Z)-4-(substituted benzylidene)-2-phenyl-4H-oxazol-5-ones (1) and compared with analogous results reported for (E)-4-benzylidene-2-phenyl-4H-furan-5-ones (5) and related compounds.

COVID-19 infection remains a threat to the health systems of many countries. Potential success in the fight against the COVID-19 pandemic is the vaccination of high-risk groups, including patients with end-stage kidney disease (ESKD) and after solid organ transplantation (SOT). Immunosuppression in kidney transplant recipients can also reduce the immunogenicity of SARS-CoV-2 vaccines (varied by vaccine platform), available data suggest that they are efficacious in approximately 50–70%, compared to non-transplant situations. In this paper, we present a newly developed acute humoral and cellular rejection with acute allograft failure and need of hemodialysis 14 days after administration of the adenovirus vectored SARS-CoV-2 vaccine (AstraZeneca; CHADOx1, AZD1222). This occurred in a patient who previously had an asymptomatic COVID-19 infection. Case reports of acute allograft rejection after vaccination against SARS-CoV-2 can help stratify risk groups of patients who develop hyperimmune reactions. However, it is also possible that those with a previous mild primary COVID-19 infection may also develop acute allograft rejections upon COVID-19 re-infection.

No abstract

No abstract